New research that uncovers the mechanism behind the newest generation of cancer drugs is opening the door for better targeted therapy. PARP inhibitors are molecular targeted cancer drugs used to treat women with ovarian cancer who have the BRCA1 and BRCA2 gene mutations. The drugs are showing promise in late-stage clinical trials for breast cancer, prostate cancer and pancreatic cancer.
Click here for original story, Discovery of mechanism behind precision cancer drug opens door for more targeted treatment
Source: ScienceDaily